GenepoweRx

What GenepoweRx does

GenepoweRx is a Hyderabad-based, private genetic testing company founded in 2019 that sells a single DNA-based pharmacogenomics test using Next-Generation Sequencing technology. The test analyzes how a patient's genes influence responses to drugs commonly prescribed for heart disease, diabetes, cancer, and other chronic conditions, with results returned within 12 days to help clinicians tailor prescriptions and reduce adverse drug reactions. The company prices the test at Rs.5,000 per individual, positioning it as India's first affordable pharmacogenomics offering relative to a global benchmark of approximately Rs.80,000.

The company's revenue model is a one-time per-test fee paid primarily through enterprise healthcare channels rather than direct-to-consumer. Its flagship commercial relationship is with AIG Hospitals in Hyderabad, announced in October 2025, which functions as both distribution and co-marketing channel. GenepoweRx is also in discussions with the Indian government to integrate genetic testing into national public health programs at a potential price point of Rs.2,000–3,000 per person, which would represent a material shift in customer segment and unit economics if executed.

GenepoweRx operates with a headcount of 11–50 employees and serves three identified segments: healthcare providers and hospital networks (primary), government health programs (in discussion), and individual patients with chronic diseases. It has no disclosed funding rounds, acquisitions, management team information, or patents, and the company is recognized as a key player in third-party wellness genomics market reports alongside established global names, though independent revenue and unit-volume data are not publicly available.

Name

GenepoweRx

Website

https://genepowerx.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Pharmacogenomics Genetic Testing Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Pharmacogenomics (PGx) Decision Support (HLAAANAB)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Pharmacogenomics testing
• DNA-based genetic tests
• Personalized medicine
• Next-generation sequencing services
• Wellness genomics

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmacogenomics Testing Services: One-time DNA-based pharmacogenomics test priced at Rs.5,000 per individual, significantly lower than the global average of approximately Rs.80,000. The test analyzes genetic profiles to help tailor prescriptions to individual patients, with results delivered within 12 days. Potential for reduced pricing (Rs.2,000-3,000 per person) if integrated into government public health programmes.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

GenepoweRx offers a DNA-based pharmacogenomics test that uses Next-Generation Sequencing technology to analyze how an individual's genes influence their response to drugs for heart disease, diabetes, cancer, and other disorders. The test is priced at Rs.5,000 per individual — significantly below the global average of ~Rs.80,000 — and delivers results within 12 days, enabling clinicians to tailor prescriptions to each patient's genetic profile.

Product overview

GenepoweRx offers a single core product — a DNA-based pharmacogenomics test utilizing Next-Generation Sequencing technology. The test analyzes genetic variations to predict individual drug responses and help tailor prescriptions to patient genetic profiles.

Differentiator

Problem solved

Functional benefit

Products and services

• DNA-based Pharmacogenomics Test A genetic test that uses Next-Generation Sequencing (NGS) technology to analyze how an individual's genes influence their response to medications for heart disease, diabetes, cancer, and other disorders. Designed for clinicians treating patients with chronic conditions where drug response is influenced by genetic variation, and delivered in partnership with hospitals (e.g., AIG Hospitals, Hyderabad) at Rs.5,000 per test with results returned within 12 days.

Quantifiable outcome

• Test results delivered within 12 days

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• AIG HospitalsflagshipStrategic or Co-development PartnerAIG Hospitals in Hyderabad has collaborated with GenepoweRx to launch India's first affordable pharmacogenomics test. The DNA-based test uses Next-Generation Sequencing technology to analyze how genes influence responses to drugs for heart disease, diabetes, cancer, and other disorders. Results are delivered within 12 days. This partnership represents a significant strategic alliance to bring personalised medicine to patients in India at an accessible price point.

Scale indicators2 records

Recent moves4 records

Expansion highlights5 records

Market position

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights6 records

Customer concentration

• Xx.com/GenepoweRx

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GenepoweRx